Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

T3011

Phase 2Biologic

IImmVira Pharma Co. Ltd

T3011 is one of 79 biologic programs targeting Advanced Melanoma. It is currently in Phase 2.

3

Indications

8

Total Trials

3

Active Trials

78

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MelanomaRecruiting

Urinary Bladder CancerRecruiting

Advanced or Metastatic Solid TumorsRecruiting

Advanced MelanomaPreclinical

Recruiting

Urinary Bladder CancerPhase 2

Recruiting

Advanced or Metastatic Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

80 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Opdivo

Bristol-Myers Squibb

Taxol

Gemzar

Johnson & Johnson

Eloxatin

Avastin

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Mfolfox6

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

PreclinicalRecruiting

Advanced Melanoma

NCT06214156

Q1 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT04370587

Q2 2029

Phase 2Recruiting

Urinary Bladder Cancer

NCT06971614

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT05602792·233 enrolled

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT05598268·74 enrolled

Colorectal Cancer2 trials

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT06200363·15 enrolled

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 1·NCT06200376·10 enrolled

Advanced Solid Tumors1 trial

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Unknown status·IImmVira Pharma Co. Ltd·Phase 1/2·NCT04780217·42 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting·IImmVira Pharma Co. Ltd·Phase 1/2·NCT04370587·30 enrolled

Urinary Bladder Cancer1 trial

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

Recruiting·IImmVira Pharma Co. Ltd·Phase 2·NCT06971614·160 enrolled

1 more indication

Advanced Melanoma1 trial

A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Preclinical·NCT06214156·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for T3011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — T3011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for T3011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmVira Pharma Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmVira Pharma Co. Ltd

Related News